Like many others we also hesitated, but now we decided to no longer operate this account and moving to 🦋. You can find us from now on @trr179.bsky.social, and we try to become more active there.

Thanks to Ralf, Marco and Stefan the TRR179 has been represented lively and very informative to the public being around at the open house at DKFZ last Sunday. It was nice seeing all those interested people around.

Read from the paper @HenrikeSalie et al "Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma" via https://t.co/e5ZLpYYu0h @teximmed2 @Uniklinik_Fr

“Survival strategies” series: Scientists R. Bartenschlager and C. Beisel, PIs of our Transregio TRR179, present our collaborative research center in an exchange with journalist Wolfgang Heim - Film clip available for viewing

We are happy to announce another great publication within the scope of our consortium. Congratulation to everyone involved! 👏😀👍 https://t.co/squRIgbJr4

Save the date! Our graduate school is organizing the International Conference on Innate Immune Checkpoints in Cancer and Tissue Damage. Heidelberg, January 2025

Do not stop emphasizing this: World Hepatitis Day: a call for increased international commitment in the fight against hepatitis

https://t.co/hWUuRzAx8Z

Congrats! Great, that we can add another success story emerging in the frame of our consortium. 👍

We are #hiring! If you are keen on understanding the role of #MAIT cells for viral infections of the liver in a fully funded PhD, join the team!! For details, see job ad below #PhD #liverimmunology @CellsMait

📣We are looking for a PhD student to join the team! 📣 If you are interested in unravelling the role of innate-like MAIT cells for viral infections of the liver, send your application! Official announcement to follow…⁦@CellsMait⁩ ⁦@TRR179_2⁩

1⃣ day to go and #EASL will open its doors! ⏲️Free for 1.5 hours on day 1? 👉Join us to discuss #HBVcure research with @TherVacB_EU 's @UlrikeProtzer @SaSi_Lens Percy Knolle Carolina Boni ➕@IPcureB's @FabienZoulim Pietro Lampertico Massimo Levrero Robert Thimme 🏥🥼💉 @EASLnews

We are happy to be one of them 😀

Die #DFG richtet zur weiteren Stärkung der #Spitzenforschung an den Hochschulen 11 neue #Sonderforschungsbereiche (SFB) ein, darunter 5 SFB/Transregio (TRR) von mehreren antragstellenden Hochschulen gemeinsam. Forschungsthemen und weitere Einzelheiten: ➡️ https://t.co/GkQPKprxlL

Congrats also from the TRR179! Well deserved 👍🏆💐

Today on set: Ralf Bartenschlager and Claudia Beisel during the television recording for the seminar series "Survival strategies", in which our TRR179 is presented. We are looking forward to the broadcast of the program and will let you know the date as soon as possible.

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial https://t.co/kQ66mCtGTU. Looking for trial participants.

Congratulations to our speaker Ralf Bartenschlager for this year's @DZIF_-Award for Translational Infection Research 2023! 👍🏆 @BartenschlagLab @CiidHeidelberg @uniklinik_hd

Finally, it’s out! I must say, I am really, really fond of this paper– if you are into #innateimmunity, the #antiviralresponse and #interferon, I think you may enjoy reading it. Nothing spectacularly new, but very comprehensive characterization of the #RIGI and #IFN pathway! 1/4

…that could/should be done or improved. I admit: this was probably not really a good lesson in terms of publication strategy (no matter my intentions, I keep falling in that trap). So: thanks everyone involved (@PichlmairL!!) for your contribution and patience! @TRR179_2